Angiogenesis markers (VEGF, soluble receptor of VEGF and angiopoietin-1) in very early arthritis and their association with inflammation and joint destruction

被引:64
作者
Clavel, Gaeelle
Bessis, Natacha [1 ]
Lemeiter, Delphine
Fardellone, Patrice
Mejjad, Othmane
Menard, Jean-Francois
Pouplin, Sophie
Boumier, Patrick
Vittecoq, Olivier
Le Loeet, Xavier
Boissier, Marie-Christophe
机构
[1] INSERM, ERI 18, Bobigny, France
[2] Univ Paris 13, Fac Med, Bobigny, France
[3] APHP, Avicenne Hosp, Dept Rheumatol, Bobigny, France
[4] CHU Amiens, Dept Rheumatol, Amiens, France
[5] CHU Rouen, Dept Biostat, Rouen, France
[6] CHU Rouen, Dept Rheumatol, Rouen, France
[7] INSERM U 519, Rouen, France
[8] IFR 23, Rouen, France
关键词
angiogenesis; rheumatoid arthritis; VEGF; angiopoietin-1;
D O I
10.1016/j.clim.2007.04.014
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objective: To investigate the involvement of angiogenesis markers in very early arthritis patients and their relevance to predict further joint destruction. Methods: Levels of Vascular Endothelial Growth Factor (VEGF), angiopoietin-1 (Ang-1), and soluble Fms-like tyrosine kinase-1 (sFlt-1) were measured by ELISA in serum samples from 310 patients having polyarthritis, evolving for less than 6 months (VErA cohort). Each angiogenesis marker was measured at baseline and one year later. X-rays of hands and feet were carried out at inclusion and after 1 year and read using the van der Heidje-modified Sharp method. Results: At baseline and after 1 year, VEGF levels were correlated with clinical and biological parameters of inflammation. We also observed a positive correlation between sFlt-1 levels and biological inflammation (Erythrocyte Sedimentation Rate (ESR): r=0.17, p=0.006; C Reactive Protein: r=0.14, p=0.02). Angiopoietin-1 levels were correlated with ESR (r=0.12, p=0.04). Interestingly, only VEGF levels measured at baseline were correlated with Disease Activity Score measured 1 year later.
引用
收藏
页码:158 / 164
页数:7
相关论文
共 39 条
[1]   Effect of etanercept on matrix metalloproteinases and angiogenic vascular endothelial growth factor: a time kinetic study [J].
Aggarwal, A ;
Panda, S ;
Misra, R .
ANNALS OF THE RHEUMATIC DISEASES, 2004, 63 (07) :891-892
[2]  
Ballara S, 2001, ARTHRITIS RHEUM, V44, P2055, DOI 10.1002/1529-0131(200109)44:9<2055::AID-ART355>3.0.CO
[3]  
2-2
[4]   Plasma angiopoietin-1, angiopoietin-2 and Tie-2 in breast and prostate cancer: a comparison with VEGF and Flt-1 [J].
Caine, GJ ;
Blann, AD ;
Stonelake, PS ;
Ryan, P ;
Lip, GYH .
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2003, 33 (10) :883-890
[5]   Recent data on the role for angiogenesis in rheumatoid arthritis [J].
Clavel, G ;
Bessis, N ;
Boissier, MC .
JOINT BONE SPINE, 2003, 70 (05) :321-326
[6]   FGF and VEGF function in angiogenesis: signalling pathways, biological responses and therapeutic inhibition [J].
Cross, MJ ;
Claesson-Welsh, L .
TRENDS IN PHARMACOLOGICAL SCIENCES, 2001, 22 (04) :201-207
[7]   Tie2 receptor tyrosine kinase, a major mediator of tumor necrosis factor α-induced angiogenesis in rheumatoid arthritis [J].
DeBusk, LM ;
Chen, Y ;
Nishishita, T ;
Chen, J ;
Thomas, JW ;
Lin, PC .
ARTHRITIS AND RHEUMATISM, 2003, 48 (09) :2461-2471
[8]   Long term anti-tumour necrosis factor α monotherapy in rheumatoid arthritis:: effect on radiological course and prognostic value of markers of cartilage turnover and endothelial activation [J].
den Broeder, AA ;
Joosten, LAB ;
Saxne, T ;
Heinegård, D ;
Fenner, H ;
Miltenburg, AMM ;
Frasa, WLH ;
van Tits, LJ ;
Buurman, WA ;
van Riel, PLCM ;
van de Putte, LBA ;
Barrera, P .
ANNALS OF THE RHEUMATIC DISEASES, 2002, 61 (04) :311-318
[9]  
Fearon U, 2003, J RHEUMATOL, V30, P260
[10]   The biology of vascular endothelial growth factor [J].
Ferrara, N ;
DavisSmyth, T .
ENDOCRINE REVIEWS, 1997, 18 (01) :4-25